Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis

毛霉病 医学 临床终点 两性霉素B 不利影响 内科学 外科 毛孔 临床试验 皮肤病科 抗真菌
作者
Francisco M. Marty,Luis Ostrosky‐Zeichner,Oliver A. Cornely,Kathleen M. Mullane,John R. Perfect,George R. Thompson,George Alangaden,Janice M. Brown,David N. Fredricks,Werner Heinz,Raoul Herbrecht,Н Н Климко,G. A. Klyasova,Johan Maertens,Sameer Melinkeri,Ilana Oren,Peter G. Pappas,Zdeněk Ráčil,Galia Rahav,Rodrigo Ribeiro dos Santos
出处
期刊:Lancet Infectious Diseases [Elsevier BV]
卷期号:16 (7): 828-837 被引量:629
标识
DOI:10.1016/s1473-3099(16)00071-2
摘要

Mucormycosis is an uncommon invasive fungal disease with high mortality and few treatment options. Isavuconazole is a triazole active in vitro and in animal models against moulds of the order Mucorales. We assessed the efficacy and safety of isavuconazole for treatment of mucormycosis and compared its efficacy with amphotericin B in a matched case-control analysis.In a single-arm open-label trial (VITAL study), adult patients (≥18 years) with invasive fungal disease caused by rare fungi, including mucormycosis, were recruited from 34 centres worldwide. Patients were given isavuconazole 200 mg (as its intravenous or oral water-soluble prodrug, isavuconazonium sulfate) three times daily for six doses, followed by 200 mg/day until invasive fungal disease resolution, failure, or for 180 days or more. The primary endpoint was independent data review committee-determined overall response-ie, complete or partial response (treatment success) or stable or progressive disease (treatment failure)-according to prespecified criteria. Mucormycosis cases treated with isavuconazole as primary treatment were matched with controls from the FungiScope Registry, recruited from 17 centres worldwide, who received primary amphotericin B-based treatment, and were analysed for day-42 all-cause mortality. VITAL is registered with ClinicalTrials.gov, number NCT00634049. FungiScope is registered with ClinicalTrials.gov, number NCT01731353.Within the VITAL study, from April 22, 2008, to June 21, 2013, 37 patients with mucormycosis received isavuconazole for a median of 84 days (IQR 19-179, range 2-882). By day 42, four patients (11%) had a partial response, 16 (43%) had stable invasive fungal disease, one (3%) had invasive fungal disease progression, three (8%) had missing assessments, and 13 (35%) had died. 35 patients (95%) had adverse events (28 [76%] serious). Day-42 crude all-cause mortality in seven (33%) of 21 primary-treatment isavuconazole cases was similar to 13 (39%) of 33 amphotericin B-treated matched controls (weighted all-cause mortality: 33% vs 41%; p=0·595).Isavuconazole showed activity against mucormycosis with efficacy similar to amphotericin B. Isavuconazole can be used for treatment of mucormycosis and is well tolerated.Astellas Pharma Global Development, Basilea Pharmaceutica International.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
4秒前
sopha发布了新的文献求助10
4秒前
tian完成签到,获得积分10
5秒前
wangmeiqiong发布了新的文献求助10
5秒前
9秒前
10秒前
JamesPei应助研友_Z1WrgL采纳,获得10
11秒前
幸运小怪兽完成签到,获得积分10
13秒前
陈佳完成签到,获得积分20
13秒前
酷炫的幻丝完成签到 ,获得积分10
13秒前
14秒前
SSSSCCCCIIII完成签到,获得积分10
14秒前
rym0404发布了新的文献求助10
15秒前
hilbertbo发布了新的文献求助10
15秒前
16秒前
ssstuck完成签到,获得积分10
16秒前
HYT发布了新的文献求助50
18秒前
ping发布了新的文献求助10
19秒前
20秒前
22秒前
失眠的狗发布了新的文献求助30
24秒前
26秒前
探寻发布了新的文献求助10
27秒前
28秒前
研友_VZG7GZ应助公孙世往采纳,获得10
28秒前
量子星尘发布了新的文献求助10
28秒前
奶昔发布了新的文献求助10
30秒前
orixero应助有只长脖鹿采纳,获得10
30秒前
天真彩虹完成签到 ,获得积分10
31秒前
32秒前
Mars_1108发布了新的文献求助10
35秒前
jiabu完成签到 ,获得积分10
35秒前
seine完成签到 ,获得积分10
38秒前
xuzj应助墨菲特采纳,获得10
38秒前
Akim应助Jing采纳,获得10
38秒前
陳拾壹发布了新的文献求助10
44秒前
烟花应助渡川采纳,获得10
44秒前
47秒前
空城完成签到 ,获得积分10
48秒前
小毛毛想睡觉完成签到 ,获得积分10
48秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976418
求助须知:如何正确求助?哪些是违规求助? 3520512
关于积分的说明 11203586
捐赠科研通 3257127
什么是DOI,文献DOI怎么找? 1798594
邀请新用户注册赠送积分活动 877804
科研通“疑难数据库(出版商)”最低求助积分说明 806523